Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 2/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | PPARG | P37231 | 5/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6026962 | 0.83 | IDO1 (0.53) | MMP12MMP1IDO1PPARGPPARA | |
| SCHEMBL6154533 | 0.81 | KMT2A (0.46) | MMP12MMP1IDO1MAOBKMT2A | |
| SCHEMBL6921092 | 0.80 | IDO1 (0.55) | MMP12MMP1IDO1PPARGPPARA | |
| SCHEMBL10175183 | 0.80 | MAOB (0.51) | MMP12MMP1IDO1PPARGPPARA | |
| SCHEMBL25290310 | 0.79 | IDO1 (0.57) | MMP12MMP1IDO1MAOBKMT2A | |
| SCHEMBL6026958 | 0.79 | MMP12 (0.49) | MMP12MMP1IDO1PPARGPPARA | |
| SCHEMBL6153385 | 0.78 | KMT2A (0.49) | MMP1IDO1MAOBKMT2AMEN1 | |
| SCHEMBL6156765 | 0.78 | MEN1 (0.49) | MMP12MMP1IDO1MAOBKMT2A | |
| SCHEMBL6154546 | 0.78 | PPARG (0.46) | MMP12MMP1PPARGPPARA | |
| SCHEMBL6153568 | 0.78 | ALDH1A1 (0.63) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050119341-A1 | 3-substituted oxyglutaric diester compound, optically active 3-substituted oxyglutaric monoester compound, and processes for producing these | UBE INDUSTRIES, LTD. (JP) | 2005-06-02 | — | — | US | disclosed |
| EP-1500642-A1 | 3-SUBSTITUTED OXYGLUTARIC DIESTER COMPOUND, OPTICALLY ACTIVE 3-SUBSTITUTED OXYGLUTARIC MONOESTER COMPOUND, AND PROCESSES FOR PRODUCING THESE | Ube Industries, Ltd. (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119341-A1 | 3-substituted oxyglutaric diester compound, optically active 3-substituted oxyglutaric monoester compound, and processes for producing these | OGDH, GLUL, ADSL | MMP12 2986/4885MMP1 4254/4885IDO1 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.